DeMuth Peter 4

What Happened

• Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, was granted 20,800 restricted stock units (RSUs) and 41,600 stock options (reported as a derivative grant) on February 2, 2026. Both awards were reported at $0.00 (no cash paid at grant). Each RSU represents the right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (filed timely, within one business day).
• Transaction code: "A" = award/grant.
• RSUs: 20,800 RSUs; acquisition price $0.00. Vesting (F1): 25% on Feb 2, 2027, then annual installments over the next three years, subject to continued service.
• Options (derivative): 41,600 options; reported as acquired at $0.00. Vesting (F2): 25% on Feb 2, 2027, then monthly vesting over the following three years, subject to continued service.
• Post-transaction holdings: Not specified in the provided filing.
• No immediate sale or purchase — these are time‑based compensation awards, not open-market trades.

Context

• These awards are time‑vested compensation; they do not represent an immediate transfer of shares to the insider and require continued service to vest.
• Reporting of $0.00 reflects grant status (no cash outlay at grant). The filing does not indicate exercise, sale, tax-withholding, or a 10b5-1 plan.